Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Overland Park, Kansas Clinical Trials

A listing of Overland Park, Kansas clinical trials actively recruiting patient volunteers.

RESULTS

Found (62) clinical trials

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Functional MR is a frequent outcome of ischemic heart disease or dilated cardiomyopathy. Patients with functional MR generally have normal valvular structures complicated by left ventricular dysfunction. Left ventricular dysfunction will often create geometric distortions that prevent complete leaflet coaptation, rendering the valve incompetent. Changes that will induce functional MR ...

Phase

0.81 miles

Learn More »

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

If participants meet all the criteria, their involvement in the study (Phases 1 and 2 described below) will last for 10-13 weeks. Participants will be asked to stay at the research site for a minimum of 2 nights on 4 separate weeks and will have 22 office visits During that ...

Phase

1.88 miles

Learn More »

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

This study looks at a new study medicine for weight management in people with overweight or obesity. The aim of this study is to find out how safe and tolerable the study medicine is. The study also looks at how the study medicine behaves in the body and how it ...

Phase

1.88 miles

Learn More »

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. ...

Phase

1.88 miles

Learn More »

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from ...

Phase

1.88 miles

Learn More »

Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

This study will be a randomized, two-part, 3-way crossover designed to evaluate the abuse liability, pharmacokinetics (PK), and product use behavior associated with study products, including VLN cigarettes, subjects' own-brand cigarettes, and nicotine polacrilex gum in healthy adult male and female exclusive smokers. Subjects will participate in a standard Screening ...

Phase

1.88 miles

Learn More »

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body. Participants will either get NNC9204-1706 (the new study medicine) or placebo (a ...

Phase

1.88 miles

Learn More »

A Phase 1 Study of CDX-0159

CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is expressed on mast cells. This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in healthy subjects.

Phase

1.88 miles

Learn More »

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Indoleamine 2,3 dioxygenase-1 (IDO1) is a target of cancer immunotherapy. Epacadostat (INCB24360) is an oral IDO1 inhibitor. IDO1 activation blocks T-cell activation, enhances T-cell apoptosis and promotes the differentiation of nave T cells to regulatory T cells (Tregs). Preclinical findings suggest that IDO1 is critical for cancers to evade immune ...

Phase

2.1 miles

Learn More »

Vaccine Enriched Autologous Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

The rate of progression free survival at one (1) year is < 20% for patients with stage IV metastatic melanoma, despite aggressive cytotoxic chemotherapy regimens and newly approved immunomodulatory and targeted therapy. Immunotherapy seems to hold the most promise for achieving prolonged survival or even cure, therefore,efforts have focused on ...

Phase

3.25 miles

Learn More »